240 related articles for article (PubMed ID: 7516373)
1. [Physiopathological aspects of the treatment of benign prostatic hypertrophy. Role of prostatic stroma and estrogens].
Solè-Balcells F
J Urol (Paris); 1993; 99(6):303-6. PubMed ID: 7516373
[TBL] [Abstract][Full Text] [Related]
2. [The role of tissue steroids in benign hyperplasia and prostate cancer].
Voigt KD; Bartsch W
Urologe A; 1987 Nov; 26(6):349-57. PubMed ID: 2448941
[TBL] [Abstract][Full Text] [Related]
3. Clinical and experimental studies of benign prostatic hyperplasia.
Coffey DS; Walsh PC
Urol Clin North Am; 1990 Aug; 17(3):461-75. PubMed ID: 1695775
[TBL] [Abstract][Full Text] [Related]
4. Androgen and prostatic stroma.
Niu YJ; Ma TX; Zhang J; Xu Y; Han RF; Sun G
Asian J Androl; 2003 Mar; 5(1):19-26. PubMed ID: 12646998
[TBL] [Abstract][Full Text] [Related]
5. Protease-activated receptor-1 upregulates fibroblast growth factor 7 in stroma of benign prostatic hyperplasia.
Wang W; Zhang X; Mize GJ; Takayama TK
Prostate; 2008 Jul; 68(10):1064-75. PubMed ID: 18386288
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical comparative analysis of transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor in normal, hyperplastic and neoplastic human prostates.
De Miguel P; Royuela ; Bethencourt R; Ruiz A; Fraile B; Paniagua R
Cytokine; 1999 Sep; 11(9):722-7. PubMed ID: 10479409
[TBL] [Abstract][Full Text] [Related]
7. [Functional morphology of the prostate].
Aumüller G
Urologe A; 1989 Nov; 28(6):306-10. PubMed ID: 2481355
[TBL] [Abstract][Full Text] [Related]
8. Benign prostatic hyperplasia and growth factors.
Lawson RK
Urologe A; 1990 Jan; 29(1):5-7. PubMed ID: 1690485
[TBL] [Abstract][Full Text] [Related]
9. Heparin-binding epidermal growth factor-like growth factor is an autocrine mediator of human prostate stromal cell growth in vitro.
Duque JL; Adam RM; Mullen JS; Lin J; Richie JP; Freeman MR
J Urol; 2001 Jan; 165(1):284-8. PubMed ID: 11125426
[TBL] [Abstract][Full Text] [Related]
10. New histopathological experimental model for benign prostatic hyperplasia: stromal hyperplasia in rats.
Mori F; Oda N; Sakuragi M; Sakakibara F; Kiniwa M; Miyoshi K
J Urol; 2009 Feb; 181(2):890-8. PubMed ID: 19095262
[TBL] [Abstract][Full Text] [Related]
11. Transactivation of ErbB1 and ErbB2 receptors by angiotensin II in normal human prostate stromal cells.
Lin J; Freeman MR
Prostate; 2003 Jan; 54(1):1-7. PubMed ID: 12481249
[TBL] [Abstract][Full Text] [Related]
12. Oestrogen and benign prostatic hyperplasia: effects on stromal cell proliferation and local formation from androgen.
Ho CK; Nanda J; Chapman KE; Habib FK
J Endocrinol; 2008 Jun; 197(3):483-91. PubMed ID: 18492814
[TBL] [Abstract][Full Text] [Related]
13. Hormones and/or growth factors in prostate hypertrophy, pathophysiology and treatment.
Mathé G
Biomed Pharmacother; 1995; 49(7-8):317-8. PubMed ID: 8562855
[No Abstract] [Full Text] [Related]
14. 4. Steroid pathophysiology of BPH. Correlative morphological and biochemical investigations on the stromal tissue of the human prostate.
Bartsch G; Daxenbichler G; Rohr HP
J Steroid Biochem; 1983 Jul; 19(1A):147-54. PubMed ID: 6193337
[TBL] [Abstract][Full Text] [Related]
15. Rationale for using aromatase inhibitors to manage benign prostatic hyperplasia. Experimental studies.
Habenicht UF; el Etreby MF
J Androl; 1991; 12(6):395-402. PubMed ID: 1722796
[TBL] [Abstract][Full Text] [Related]
16. Benign prostatic hyperplasia (BPH) epithelial cell line BPH-1 induces aromatase expression in prostatic stromal cells via prostaglandin E2.
Wu Q; Zhou Y; Chen L; Shi J; Wang CY; Miao L; Klocker H; Park I; Lee C; Zhang J
J Endocrinol; 2007 Oct; 195(1):89-94. PubMed ID: 17911400
[TBL] [Abstract][Full Text] [Related]
17. Role of estrogens in human benign prostatic hyperplasia.
Sciarra F; Toscano V
Arch Androl; 2000; 44(3):213-20. PubMed ID: 10864369
[TBL] [Abstract][Full Text] [Related]
18. Profiling molecular targets of TGF-beta1 in prostate fibroblast-to-myofibroblast transdifferentiation.
Untergasser G; Gander R; Lilg C; Lepperdinger G; Plas E; Berger P
Mech Ageing Dev; 2005 Jan; 126(1):59-69. PubMed ID: 15610763
[TBL] [Abstract][Full Text] [Related]
19. [The current approach to the management of benign hypertrophy of the prostate].
Abbou CC; Salomon L; Chopin D; Ravery V; Haillot O
Ann Urol (Paris); 1996; 30(6-7):294-301; discussion 302-10. PubMed ID: 9092383
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical analysis of the IL-6 family of cytokines and their receptors in benign, hyperplasic, and malignant human prostate.
Royuela M; Ricote M; Parsons MS; García-Tuñón I; Paniagua R; de Miguel MP
J Pathol; 2004 Jan; 202(1):41-9. PubMed ID: 14694520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
